Product Images Incruse Ellipta
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 19 images provide visual information about the product associated with Incruse Ellipta NDC 0173-0873 by Glaxosmithkline Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Umeclidinium chemical structure - incruse ellipta spl graphic 01
Figure 1. Impact of Intrinsic and Extrinsic Factors on the Systemic Exposure of Umeclidinium - incruse ellipta spl graphic 02
This text provides information on the population demographics (age and gender) and their potential impact on drug exposure (AUC and Cmax) for various medical conditions such as severe renal impairment and moderate hepatic impairment. The text also mentions the effect of Conax, a €YP2D6 inhibitor, and Veraparmil, a P-gp transport inhibitor, on AUC. The fold change and 90% CI are also indicated in the text, which suggests that no dose adjustment is required for the given conditions.*
Figure 2. Adjusted Mean Change from Baseline in Postdose Serial FEV1 (mL) on Days 1 and 7, Day 1 - incruse ellipta spl graphic 03
This text appears to be a table or graph displaying adjusted mean changes in FEV (forced expiratory volume) measured in mL over time for two different treatments, placebo and Umedidinim (at different doses). There are five data points for each treatment, but the specific time frame or duration of the study is not provided. The text also includes dosages for Umedidinim at 156 mc, 3125 mcg, 125 mcg, and 625 mcg, with some reference to dosing schedule. However, without additional context or explanation, the significance or interpretation of these numbers is not clear.*
Figure 2. Adjusted Mean Change from Baseline in Postdose Serial FEV1 (mL) on Days 1 and 7, Day 7 - incruse ellipta spl graphic 04
Figure 3. Least Squares (LS) Mean Change from Baseline in FEV1 (mL) over Time (0-24 h) on Days 1 and 168 (Trial 1 Subset Population), Day 1 - incruse ellipta spl graphic 05
Figure 3. Least Squares (LS) Mean Change from Baseline in FEV1 (mL) over Time (0-24 h) on Days 1 and 168 (Trial 1 Subset Population), Day 168 - incruse ellipta spl graphic 06
The text appears to be a statistical output and indicates the change from baseline in milliliters for a placebo group and a group receiving Umeclidinium 625 mcg ek at 2 hours. The rest of the output is not available.*
Parts figure - incruse ellipta spl graphic 07
This is a generic and brief product description. The text indicates that there is a tray lid and a carton, but no specific details are provided. It could represent any product that includes these components.*
IFU Figure A.JPG - incruse ellipta spl graphic 08
IFU Figure B - incruse ellipta spl graphic 09
IFU Figure C.JPG - incruse ellipta spl graphic 10
IFU Figure D.JPG - incruse ellipta spl graphic 11
This text is not useful and cannot be evaluated because it consists of random characters and symbols.*
IFU Figure E - incruse ellipta spl graphic 12
IFU Figure F - incruse ellipta spl graphic 13
IFU Figure G.JPG - incruse ellipta spl graphic 14
IFU Figure I.JPG - incruse ellipta spl graphic 15
IFU Figure I - incruse ellipta spl graphic 16
IFU Figure J.JPG - incruse ellipta spl graphic 17
IFU Figure K.jpg - incruse ellipta spl graphic 18
Incruse Ellipta 30 count carton - incruse ellipta spl graphic 19
INCRUSE is a prescription medication that comes in an inhalation powder form for oral inhalation only. Each blister contains 62.5 mcg of umedlidinium, magnesium stearate, and lactose monohydrate. The medication is delivered with an ELLIPTA inhaler that contains 1 Fol Strip of 30 blisters. NDC code is 0173-0873-10.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.